Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1502)	3/6/1998 10:47:00 AM
From: Dana Winrow	Read Replies (3) \| Respond to of 1894

A few comments on some of the points made about AccuMed's positioning in the cytology marketplace: The AcCell Cytopathology System's modular component approach has benefits for all sizes of laboratories, including the major reference labs that tend to be more "production-oriented". No matter the size of the laboratory, the unique benefit of cost reduction is only realized by AccuMed's system (see acta-cytol.com -- "Impact of Automated Technology on the Cervical Cytologic Smear A Comparison of Cost", Acta Cytol 1998;42:165-170). Each lab, regardless of size, has unique challenges to address (ranging from personnel issues to QC requirements) and the AcCell system can be implemented to serve as a strategic business machine as well as a laboratory tool in a variety of laboratory settings. An additional fact to consider with the pay-for-use issue: there is a slide-usage fee with the TracCell Slide Mapping System. Dana Winrow Investor Relations AccuMed International, Inc. ir@accumed.com